{"disease":{"id":"advanced-renal-cell-carcinoma-arcc","name":"advanced renal cell carcinoma arcc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06345183","title":"Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":327,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04957160","title":"Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination","phase":"","overall_status":"COMPLETED","enrollment_count":281,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT07159191","title":"Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}